Could a drug combo tame deadly pancreatic cancer?

NCT ID NCT06953999

Recruiting now Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This large Phase 3 trial tests whether adding two immune-boosting drugs (ivonescimab and AK117) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 participants will be randomly assigned to get the new drugs or a placebo, all with chemo. The goal is to see if the combination improves survival and slows cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab and AK117 (immune-boosting drugs) plus chemotherapy (albumin-bound paclitaxel and gemcitabine)
What this could lead to: If it works, this could offer a new first-line treatment option that helps people with metastatic pancreatic cancer live longer.
What could go wrong: This is an early-stage Phase 3 trial, so results are not guaranteed. The drugs may cause side effects like immune reactions or infections, and the benefit over standard chemotherapy is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 20032, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.